- Home
- SCWO vs CUE Comparison
SCWO vs CUE Comparison
Compare SCWO & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCWO | CUE |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.2M | 27.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SCWO | CUE |
|---|---|---|
| Price | $2.51 | $0.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 42.0K | ★ 343.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,287,000.00 |
| Revenue This Year | $5,945.19 | N/A |
| Revenue Next Year | $106.82 | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $0.16 | $0.23 |
| 52 Week High | $3.55 | $1.12 |
Technical Indicators
Market Signals| Indicator | SCWO | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 49.04 |
| Support Level | $2.33 | $0.26 |
| Resistance Level | $3.10 | $0.36 |
| Average True Range (ATR) | 0.21 | 0.02 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 18.87 | 55.54 |
Price Performance
Historical ComparisonAbout SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.